Referenzen Saxenda® Liraglutid FAQ

Auf dieser Seite finden Sie eine ausführliche Liste der wissenschaftlichen Referenzen, die für die Artikel in unserem FAQ-Bereich über Saxenda® (Liraglutid) verwendet wurden. Diese Quellen wurden sorgfältig aus renommierten Datenbanken wie PubMed und anderen wissenschaftlichen Plattformen ausgewählt. Die Referenzen stammen aus führenden medizinischen Fachzeitschriften, wissenschaftlichen Veröffentlichungen und offiziellen Gebrauchsinformationen. Sie bieten einen fundierten Einblick in die Wirksamkeit, Sicherheit und Anwendung von Saxenda® beim Gewichtsmanagement.

1. Dose Response Effects of Liraglutide (Saxenda) on Weight Loss among Overweight and Obese Individuals (2024). Athens Journal of Health. Verfügbar unter: https://www.athensjournals.gr/health/2024-11-1-4-Rajar.pdf

2. Medications for Obesity: A Review (2024). Journal of the American Medical Association. Verfügbar unter: https://pubmed.ncbi.nlm.nih.gov/39037780/

3. Real‐Life Use of Liraglutide 3 mg in Obesity Management: The SAX‐RL Study (2024). Diabetes, Obesity and Metabolism. Verfügbar unter: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15845

4. Liraglutide 3.0 mg (Saxenda) for Weight Loss and Remission of Pre-Diabetes (2024). Obesity Surgery. Verfügbar unter: https://link.springer.com/article/10.1007/s11695-023-06895-7

5. Liraglutide (Saxenda) Combined with Lifestyle Coaching for Weight Loss in a Bariatric Center (2024). Journal of Surgery. Verfügbar unter: https://journalonsurgery.org/articles/js-v4-1157.html

6. One-Year Weight Reduction with Semaglutide or Liraglutide in Clinical Practice (2024). JAMA Network Open. Verfügbar unter: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823644

7. Saxenda, Werkzame stof: liraglutide (2024). Apotheek.nl. Verfügbar unter: https://www.apotheek.nl/medicijnen/liraglutide?product=saxenda

8. Saxenda (2024). Novo Nordisk. Verfügbar unter: https://www.saxenda.com/

9. Highlights of Prescribing Information (2024). Novo Nordisk. Verfügbar unter: https://www.novo-pi.com/saxenda.pdf

10. Prikinstructies (2024). Novo Nordisk. Verfügbar unter: https://www.saxenda.com/about-saxenda/how-to-use-the-pen.html

11. Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism (2024). Diabetes & Metabolism Journal. Verfügbar unter: https://www.e-dmj.org/journal/view.php?number=2843

12. Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis (2024). Therapeutic Advances in Neurological Disorders. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11437580/

13. Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks (2024). Obesity Pillars Journal. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11404059/

14. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity (2024). Diabetes Care. Verfügbar unter: https://diabetesjournals.org/care/article/47/11/1873/156807/Efficacy-and-Safety-of-GLP-1-Medicines-for-Type-2

15. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials (2024). Diabetologia. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11153294/

16. Glucagon‐like peptide‐1 receptor agonists and kidney outcomes (2024). Journal of Diabetes. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11450654/

17. Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide (2024). Cardiovascular Diabetology. Verfügbar unter: https://cardiab.biomedcentral.com/articles/10.1186/s12933-024-02319-7

18. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis (2024). British Medical Journal. Verfügbar unter: https://www.bmj.com/content/384/bmj-2023-076410.long

19. Productkenmerken (2024). Novo Nordisk. Verfügbar unter: https://www.ema.europa.eu/nl/documents/product-information/saxenda-epar-product-information_nl.pdf

20. Medications for the Treatment of Obesity (2023). Journal of Visceral Surgery. Verfügbar unter: https://www.sciencedirect.com/science/article/abs/pii/S187878862200176X

21. Obesity Management in Adults A Review (2023). Journal of the American Medical Association. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11325826/

22. A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications (2023). Life. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC10144237/

23. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials (2023). International Journal of Molecular Sciences. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC10341852/

24. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial (2023). Cardiovascular Diabetology. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC9960425/

25. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes (2023). Diabetes, Obesity and Metabolism. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC10544709/

26. Beyond glycemia: Comparing tirzepatide to GLP-1 analogues (2023). Reviews in Endocrine and Metabolic Disorders. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC10697893/

27. Glucagon‐like peptide agonists: A prospective review (2023). Endocrinology, Diabetes & Metabolism. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC10782143/

28. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation (2023). The Lancet. Verfügbar unter: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00059-7/fulltext

29. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss (2023). Journal of the American Medical Association. Verfügbar unter: https://jamanetwork.com/journals/jama/fullarticle/2810542

30. Obesity Management in Adults A Review (2023). Journal of the American Medical Association. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11325826/

31. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022 (2023). American Pharmacists Association. Verfügbar unter: https://www.sciencedirect.com/science/article/pii/S1544319123003096

32. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials (2023). International Journal of Molecular Sciences. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC10341852/

33. The Effects and Side Effects of Liraglutide as a Treatment for Obesity (2022). Cardiovascular Prevention and Health. Verfügbar unter: https://synapse.koreamed.org/articles/1516079546

34. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight (2022). Clinical Epidemiology. Verfügbar unter: https://www.dovepress.com/efficacy-and-safety-of-liraglutide-and-semaglutide-on-weight-loss-in-p-peer-reviewed-fulltext-article-CLEP

35. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults (2022). Journal of the American Medical Association. Verfügbar unter: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753508/

36. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (2022). Journal of the American Medical Association. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC8753508/

37. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review (2022). Clinical Epidemiology. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC9738168/

38. Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022). Nature Communications. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC9378667/

39. Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review (2022). Therapeutic Advances in Chronic Disease. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC9260566/

40. Factors associated with successful weight loss after liraglutide treatment for obesity (2022). Diabetes, Obesity and Metabolism. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC9812862/

41. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases (2022). Journal of the American Medical Association. Verfügbar unter: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2790392

42. Effects of Liraglutide on Gastrointestinal Functions and Weight in Obesity: A Randomized Clinical and Pharmacogenomic Trial (2022). Obesity. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC9335902/

43. Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022). Nature. Verfügbar unter: https://www.nature.com/articles/s41467-022-32307-y

44. Effects of Liraglutide on Visceral and Ectopic Fat in Adults with Overweight and Obesity (2021). The Lancet Diabetes & Endocrinology. Verfügbar unter: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00179-0/abstract

45. Energy Intake as a Short‐Term Biomarker for Weight Loss in Adults with Obesity Receiving Liraglutide (2021). Obesity Science & Practice. Verfügbar unter: https://onlinelibrary.wiley.com/doi/10.1002/osp4.486

46. Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021). New England Journal of Medicine. Verfügbar unter: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

47. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists (2021). Advances in Therapy. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC8189979/#Abs1

48. Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis (2021). eClinicalMedicine. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC8633575/

49. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists (2021). Advances in Therapy. Verfügbar unter: https://link.springer.com/article/10.1007/s12325-021-01710-0

50. Productkenmerken (2020). Novo Nordisk. Verfügbar unter: https://www.ema.europa.eu/nl/documents/product-information/saxenda-epar-product-information_nl.pdf

51. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial (2020). Obesity. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC7065111/

52. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial (2020). Diabetes Care. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC7171937/

53. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial (2020). Diabetes Care. Verfügbar unter: https://diabetesjournals.org/care/article/43/5/1085/35698/Efficacy-and-Safety-of-Liraglutide-3-0-mg-in

54. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial (2020). Obesity. Verfügbar unter: https://onlinelibrary.wiley.com/doi/10.1002/oby.22726

55. Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance (2020). Clinical Diabetes. Verfügbar unter: https://diabetesjournals.org/clinical/article/38/4/390/35426/Switching-Between-Glucagon-Like-Peptide-1-Receptor

Gemeinsam auf dem Weg zu einem gesünderen Leben – ärztlich begleitet und auf Ihre persönlichen Ziele abgestimmt.

Die Inhalte dieser Referenzliste dienen ausschließlich allgemeinen Informationszwecken. Die aufgeführten Artikel und Quellen basieren auf öffentlich zugänglichen wissenschaftlichen Veröffentlichungen und beziehen sich auf die Anwendung von Saxenda® und damit verbundene Behandlungen. Trotz sorgfältiger Auswahl und Zusammenstellung der Informationen empfehlen wir Ihnen, vor medizinischen Entscheidungen immer professionellen ärztlichen Rat einzuholen. BMI Care übernimmt keine Haftung für mögliche Fehler oder Unvollständigkeiten der bereitgestellten Informationen.

Weitere Hintergrundinformationen und wissenschaftliche Grundlagen finden Sie auf unserer Seite Quellen.